Prostate stem cell antigen is overexpressed in prostate cancer metastases - Test2 - elhamkhani - TriplyDB

Prostate stem cell antigen is overexpressed in prostate cancer metastases

Prostate stem cell antigen is overexpressed in prostate cancer metastases

http://www.wikidata.org/entity/Q28243809

about

Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance Prostate cancer relevant antigens and enzymes for targeted drug delivery Cellular Plasticity in Prostate Cancer Bone Metastasis Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy Inflammation meets cancer, with NF-κB as the matchmaker Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time.A loss-of-function RNA interference screen for molecular targets in cancer.A library of gene expression signatures to illuminate normal and pathological lymphoid biology.The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis.Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody Prostate stem cell antigen: a Jekyll and Hyde molecule?Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice Epigenetics of prostate cancer: beyond DNA methylation Genetic variation in the prostate stem cell antigen gene and upper gastrointestinal cancer in white individuals.Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer.Association between PSCA mRNA expression levels and rs2294008 polymorphism in transitional cell cancer of the bladder.NF-κB signaling pathways regulated by CARMA family of scaffold proteins.A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin.Inhibition of Canonical NF-κB Signaling by a Small Molecule Targeting NEMO-Ubiquitin Interaction Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.The Quantified Level of Circulating Prostate Stem Cell Antigen mRNA relative to GAPDH Level Is a Clinically Significant Indictor for Predicting Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy.TGF-β and NF-κB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial Knockdown of PSCA induces EMT and decreases metastatic potentials of the human prostate cancer DU145 cells.NF-kappa B as a target for cancer therapy.Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors Bortezomib in mantle cell lymphoma.Prostate stem cell antigen: a prospective therapeutic and diagnostic target.Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies.A dual role for Caspase8 and NF-κB interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer.Emerging therapies for B-cell non-Hodgkin lymphoma.Novel disease targets and management approaches for diffuse large B-cell lymphoma.Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.Prospects in radionuclide imaging of prostate cancer.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications.Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.

P2860

Q24646761-631B8B24-2812-4D1E-B1AE-91596AD22D7D Q27013843-16E91F27-CF15-4793-AE96-7666BCBBF5C5 Q28085013-3A2FEFA3-B219-443D-8F25-CD37C46D3319 Q28550782-73D13FE7-0ED8-43D4-A805-42C479839391 Q29620242-D4D8C9C5-38C9-4553-8ED9-04AAD4DB36D4 Q30728281-A7A9789F-912E-42D2-9BB4-2531DF17D9D0 Q33237976-A52475EF-4C58-4BFD-8D73-1C2CE6A85D52 Q33240316-B83C877D-A58D-4CF8-8220-15AE00B999B7 Q33254825-55D44EE9-4970-4E6F-AD05-6F664145C9EB Q33738280-85BE848F-3E1C-416E-8AA6-E3495CD525F5 Q34001130-5FBB941E-E56C-413A-A7B2-13D5A62F4E5B Q34472125-D4639F28-E046-46AD-A5B0-AAA9E54C5293 Q34505232-6FF76288-DC1D-4669-9EA1-6260EE3AB761 Q34543335-7520FADC-7BCC-4252-80B2-872833ACD64E Q34717742-4C4D3D70-EF48-4EAD-8A65-2E1F39484345 Q34993937-A7ED9A64-894B-4D3E-83C4-D4DCA9C16C87 Q35347919-E219987F-02A8-4E50-9155-FBD38E304026 Q35790227-6F68B888-A473-4D4E-A594-B5A9A557C865 Q35887748-5232E3FA-81FE-455B-9464-F3B99582E1F0 Q36021623-DBDA9400-DB17-4AF6-8622-6EC94EB9187E Q36191947-7D76A78F-ED70-4BE5-88F5-DC2D74FF8C1F Q36210115-1C4534D4-41D2-4CB3-9FC8-8BA5E5E62DD3 Q36278113-A67EC672-F27F-4301-9D7E-F3CF73E86E37 Q36650373-880868EE-8701-4D09-AAB6-40A3CB13503E Q36687126-478B646B-FE13-4EAC-BDF6-916AE366894F Q36709532-726B9518-57DF-408F-A93C-4CB879A52925 Q37101581-CB3684BB-279A-40BA-B17F-FB5FA18263CE Q37136989-69CF4FD4-F520-495A-9D16-EE57255F75CC Q37186552-F997331C-7AF2-426C-ADFE-1CCFC3A1F7B5 Q37289040-6B7B705D-F123-4DCA-9426-FE5DF6A9962B Q37330181-1D3EB225-890B-46D6-8954-206A71937ABA Q37544113-E2FF6B94-8F7F-4831-87E2-AD3CF4DE7075 Q37589257-ED988C71-DEE4-4129-8AC3-CFB1055AC964 Q37598947-4C0E7DA4-9ACF-42BB-924D-45CBA90E5C32 Q37775632-00962DE4-35E6-4AC7-A68C-93FCE584778A Q37840104-0FD0931D-D69C-40BE-9E0E-F74B8CC40761 Q37962869-BCA461E9-83A4-4ADA-B23F-3E11CCD36F44 Q38161760-0FCFCAC9-9D93-4569-A8CF-ACEE5251BADE Q38168921-0453C1B6-4B5A-44E4-9757-317E41FF4520 Q38179500-C1AA0B33-6A10-4DBE-A336-3E4B281F82D9

P2860

Prostate stem cell antigen is overexpressed in prostate cancer metastases

http://www.wikidata.org/entity/Q28243809

description

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 2005

@ast

im April 2005 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: April 2005)

@en

vedecký článok (publikovaný 2005/04/01)

@sk

vědecký článek publikovaný v roce 2005

@cs

wetenschappelijk artikel (gepubliceerd op 2005/04/01)

@nl

наукова стаття, опублікована у квітні 2005

@uk

مقالة علمية (نشرت في أبريل 2005)

@ar

name

Prostate stem cell antigen is overexpressed in prostate cancer metastases

@ast

Prostate stem cell antigen is overexpressed in prostate cancer metastases

@en

Prostate stem cell antigen is overexpressed in prostate cancer metastases

@nl

type

label

Prostate stem cell antigen is overexpressed in prostate cancer metastases

@ast

Prostate stem cell antigen is overexpressed in prostate cancer metastases

@en

Prostate stem cell antigen is overexpressed in prostate cancer metastases

@nl

prefLabel

Prostate stem cell antigen is overexpressed in prostate cancer metastases

@ast

Prostate stem cell antigen is overexpressed in prostate cancer metastases

@en

Prostate stem cell antigen is overexpressed in prostate cancer metastases

@nl

P1433

Q28243809-09752F4D-6E0F-406B-8240-AF54EC2A20AB

P1476

Q28243809-3D20AC70-67C9-4DA0-B7EE-A9F25FFF04AC

P2093

Q28243809-5060657D-0C7E-4E55-98E0-53472F4D7BB7

Q28243809-7CC73285-326C-4D33-9E51-9B2A8A312A8D

Q28243809-9664299A-DAB4-4528-9561-84448F7D2DA4

Q28243809-9AEABBD6-BD12-4B4B-8ACF-F5BEF2C2B4E3

Q28243809-AA5DD2F2-15FB-4063-8D15-A6DBE62CCD86

Q28243809-BE8BD040-8D04-4F94-B020-4079405915EA

Q28243809-C1535F00-0E45-49D4-9E32-CC3A4F625E95

Q28243809-C20EB52D-C9DD-4519-A7B8-38220256091E

P304

Q28243809-A968B91D-7BC4-4CE7-8DB7-D4A33C17B3AE

P31

Q28243809-4425D675-3EC2-4DFE-A100-42D9438C6FF6

P3181

Q28243809-918C0EEA-FBD1-4828-99D3-3C27CD38F776

P356

Q28243809-042E96DA-2EC8-491B-B27E-8691776D20FE

P407

Q28243809-0D7F21C3-00E8-4F9A-8F35-94E1EB2D9AEC

P433

Q28243809-6B500F4E-6963-4679-BF0F-E39EE58245AB

P478

Q28243809-9FCA392A-A79A-435F-A5E5-D0139021BD37

P577

Q28243809-4A7E8166-6B78-4D44-9E78-6E4B1B96004A

P698

Q28243809-61CC69F6-410E-4A46-B8CF-A2E7FD814AA9

P921

Q28243809-2E71EA88-5EE1-4385-8235-CBCA4A42F872

P3181

P356

1078-0432.CCR-04-1842

P1433

Clinical Cancer Research

P1476

Prostate stem cell antigen is overexpressed in prostate cancer metastases

@en

P2093

I Peter Shintaku

http://www.w3.org/2001/XMLSchema#string

John S Lam

http://www.w3.org/2001/XMLSchema#string

Jonathan W Said

http://www.w3.org/2001/XMLSchema#string

Joyce Yamashiro

http://www.w3.org/2001/XMLSchema#string

Robert B Jenkins

http://www.w3.org/2001/XMLSchema#string

Robert E Reiter

http://www.w3.org/2001/XMLSchema#string

Robert L Vessella

http://www.w3.org/2001/XMLSchema#string

Steve Horvath

http://www.w3.org/2001/XMLSchema#string

P304

2591-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3767070

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-04-1842

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15814638

http://www.w3.org/2001/XMLSchema#string

P921